Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbamazepine for skeletal dysplasia in children
ISRCTN37815869Phase 2Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Apr 2019
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of carbamazepine in osteochondrodysplasia and Schmid metaphyseal chondrodysplasia (MCDS) (2 arms), sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoints: Laboratory safety assessments, adverse events and physical examinations, Dose-titration safety review and 2 more. Started Apr 2019; status: completed.
02
Drugs
carbamazepine
03
Conditions
osteochondrodysplasiaSchmid metaphyseal chondrodysplasia (MCDS)
Beyond the preview
Go deeper on ISRCTN37815869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN37815869.